3a,8b-cis-dihydro-3H-5-bromo-cyclopenta[b]benzofuran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 3a,8b-cis-dihydro-3H-5-bromo-cyclopenta[b]benzofuran
• 英文别名: 3a,8b-dihydro-3H-5-bromocyclopenta[b]benzofuran；3a,8b-cis-dihydro-3H-5-bromocyclopenta[b]benzofuran；5-bromo-3a,8b-dihydro-3H-cyclopenta[b][1]benzofuran
• 化学式: C₁₁H₉BrO
• 分子量: 237.096
• InChiKey: ZSTWUTDRRGELCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3a,8b-cis-dihydro-3H-5-bromo-cyclopenta[b]benzofuran 、 4-碘丁基四氢吡喃基醚 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 以86.2%的产率得到3a,8b-cis-dihydro-3H-5-(4-tetrahydropyranyloxy-n-butyl)cyclopenta[b]benzofuran
  参考文献：
  名称：

  5,6,7-Trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives

  摘要：

  具有药用价值的化合物是5,6,7-三去氧-4,8-互-m-苯基PGI.sub.2衍生物，例如5,6,7-三去氧-4,8-互-m-苯基-16,17,18,19,20-五去氧-15-苯基PGI.sub.2。

  公开号：

  US04301164A1
• 作为产物：
  描述：

  3,5-cis-bis(2,6-dibromophenoxy)cyclopentene 在 正丁基锂 、 ammonium chloride 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 3a,8b-cis-dihydro-3H-5-bromo-cyclopenta[b]benzofuran
  参考文献：
  名称：

  5,6,7,-Trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives and

  摘要：

  药用化合物是5,6,7-三缺一-4,8-相间-间苯二酚 PGI.sub.2 衍生物，例如 5,6,7-三缺一-4,8-相间-间苯二酚-13,14-二去氢 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-16,16-二甲基 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-17-.alpha.-甲基-20-同源 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-17,18,19,20-四缺一-16-苯氧基 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-20-异丙亚甲基 PGI.sub.2，5,6,7-三缺一-4,8-相间-(5-甲基-1,3-苯基) PGI.sub.2，和 5,6,7-三缺一-4,8-相间-间苯二酚-2,3-二去氢-16,17,18,19,20-五缺一 5-苯基 PGI.sub.2。它们在治疗溃疡、血栓和高血压等方面具有用途。

  公开号：

  US04564620A1

文献信息

• 5,6,7,-trinor-4,8-inter-m-phenylene 2-nor PGI.sub.2 derivatives and
  申请人：Toray Industries, Inc.

  公开号：US04822804A1

  公开（公告）日：1989-04-18

  Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl-.omega.-homo PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl-.omega.-homo PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl-.omega.-homo PGI.sub.2, 5,6, 7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16-p ropoxy PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-et ho xy PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-pr op oxy PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16-phenoxy PGI.sub.2 and methyl esters thereof. 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16 -phenoxy PGI.sub.2 or its methyl ester, 5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16-methyl-16-phe nox y PGI.sub.2 or its methyl ester. They are useful in treatment of ulcers, thrombii and hypertension for example.

  药用化合物是5,6,7-三去氢-4,8-间-m-苯撑PGI.sub.2衍生物，如5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-16,16-二甲基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-17(S)-甲基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-17(R)-甲基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-16,16-二甲基-ω-同系PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-17(S)-甲基-ω-同系PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2-去氢-17(R)-甲基-ω-同系PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2,17,18,19,20-五去氢-16,16-二甲基-16-丙氧基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2,18,19,20-四去氢-16,16-二甲基-17-乙氧基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2,18,19,20-四去氢-16,16-二甲基-17-丙氧基PGI.sub.2，5,6,7-三去氢-4,8-间-m-苯撑-2,17,18,19,20-五去氢-16-苯氧基PGI.sub.2及其甲酯。5,6,7-三去氢-4,8-间-m-苯撑-2,17,18,19,20-五去氢-16,16-二甲基-16-苯氧基PGI.sub.2或其甲酯，5,6,7-三去氢-4,8-间-m-苯撑-2,17,18,19,20-五去氢-16-甲基-16-苯氧基PGI.sub.2或其甲酯。它们可用于治疗溃疡、血栓和高血压等疾病。
• 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0024943A1

  公开（公告）日：1981-03-11

  Pharmaceutically useful compounds possessing platelet aggregation-inhibiting and hypotensive anti-ulcer activity and having improved stability as compared with Prostaglandin I2 (PGI2) are provided by 5,6,7-trinor-4,8-inter-m-phenylene PGI2 derivatives such as 5,6,7-trinor-4, 8-inter-m-phenylene- 16,17,18,19,20- pentanor-15-phenyl PGI2. Also, pharmaceutical compositions containing them.

  与前列腺素 I2 (PGI2)相比，5,6,7-三去甲-4,8-间亚苯基 PGI2 衍生物具有抑制血小板聚集和降压抗溃疡活性，并具有更好的稳定性，例如 5,6,7-三去甲-4,8-间亚苯基-16,17,18,19,20-戊-15-苯基 PGI2。 此外，还提供了含有这些化合物的药物组合物。
• US4301164A
  申请人：——

  公开号：US4301164A

  公开（公告）日：1981-11-17
• 5,6,7,-Trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives and
  申请人：Toray Industries, Inc.

  公开号：US04564620A1

  公开（公告）日：1986-01-14

  Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as 5,6,7-trinor-4,8-inter-m-phenylene-13,14-didehydro PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-16,16-dimethyl PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-17-.alpha.-methyl-20-homo PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-17,18,19,20-tetranor-16-phenoxy PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-20-isopropylidene PGI.sub.2, 5,6,7-trinor-4,8-inter-(5-methyl-1,3-phenylene) PGI.sub.2, and 5,6,7-trinor-4,8-inter-m-phenylene-2,3-didehydro-16,17,18,19,20-pentanor-1 5-phenyl PGI.sub.2. They are useful in treatment of ulcers, thrombii and hypertension for example.

  药用化合物是5,6,7-三缺一-4,8-相间-间苯二酚 PGI.sub.2 衍生物，例如 5,6,7-三缺一-4,8-相间-间苯二酚-13,14-二去氢 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-16,16-二甲基 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-17-.alpha.-甲基-20-同源 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-17,18,19,20-四缺一-16-苯氧基 PGI.sub.2，5,6,7-三缺一-4,8-相间-间苯二酚-20-异丙亚甲基 PGI.sub.2，5,6,7-三缺一-4,8-相间-(5-甲基-1,3-苯基) PGI.sub.2，和 5,6,7-三缺一-4,8-相间-间苯二酚-2,3-二去氢-16,17,18,19,20-五缺一 5-苯基 PGI.sub.2。它们在治疗溃疡、血栓和高血压等方面具有用途。
• 5,6,7-Trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives
  申请人：Toray Industries, Inc.

  公开号：US04301164A1

  公开（公告）日：1981-11-17

  Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as 5,6,7-trinor-4,8-inter-m-phenylene-16,17,18,19,20-pentanor-15-phenyl PGI.sub.2.

  具有药用价值的化合物是5,6,7-三去氧-4,8-互-m-苯基PGI.sub.2衍生物，例如5,6,7-三去氧-4,8-互-m-苯基-16,17,18,19,20-五去氧-15-苯基PGI.sub.2。